focus -WSS

focus

author：knowledge 2025-09-29 20:52:00 - browse：53588

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Inside the fall of star MIT scientist David Sabatini

focus

WSS

Pfizer's Covid pill remains 89% effective in final analysis, company says

How many hemophilia patients actually want gene therapy?

Pushing for an NIH office for post

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Option Care buys Amedisys in $3.6 billion home care deal

Change Healthcare outage fallout shows need for new oversight

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Heart attack and stroke risk calculators need revising

Inside the fall of star MIT scientist David Sabatini

Dobbs anniversary: the lost opportunity of abortion as health care

How to save health care price transparency rules

Peter Hotez and the public health issue of online harassment

Pushing for an NIH office for post

DIEP, the 'gold standard' of breast reconstruction, is under threat

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Affirmative action in medical school literally saved lives

Connecting traumatic brain injury and domestic violence

explore

EPA limits use of carcinogenic gas for sterilizing medical devices

Listen: PBM conflicts, RSV vaccines, & the future of flu season

RaDonda Vaught case: a double standard for nurses, physicians

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

focus

focus

explore

leisure time